Haoxi Health locks in $4M registered direct offering at $0.40/share, layering on pre-funded warrants

summarizeSummary

Haoxi Health Technology finalizes a $4 million registered direct offering at $0.40 per share with 9.7 million pre-funded warrants, securing critical capital but imposing massive dilution risk on existing shareholders.

check_boxKey Events · Financing and Capital Events · HAO

• $4M Registered Direct Offering Priced at $0.40/Share

  Haoxi Health is selling 300,000 Class A Ordinary Shares at $0.40 per share and 9,700,000 pre-funded warrants (exercise price $0.33) for gross proceeds of up to $4 million. The offering price represents a premium to the current market price of $0.2581, but the warrants create a massive overhang.

• Extreme Dilution from Pre-Funded Warrants

  Should all 9.7 million pre-funded warrants be exercised, total outstanding Class A Ordinary Shares would balloon from 1.9 million to 11.9 million, diluting existing shareholders by over 80%. The warrants are exercisable immediately and carry no expiration.

• Net Proceeds of ~$3.59 Million for Working Capital

  After placement agent fees (7.0% of gross proceeds plus 0.5% expense reimbursement and up to $60,000 in expenses), net proceeds are estimated at approximately $3.59 million. The funds will be directed to general corporate purposes, including operating expenses and business development.

• 90-Day Lock-Up for Insiders

  Directors, officers, and 5%+ shareholders have agreed to a 90-day lock-up period post-closing, restricting sales of additional shares. This offers some short-term protection against immediate insider selling.

auto_awesomeAnalysis · HAO · Trade & Services

Haoxi Health Technology is raising $4 million through a registered direct offering, selling 300,000 Class A Ordinary Shares at $0.40 each alongside 9,700,000 pre-funded warrants exercisable at $0.33. While the offering price sits at a premium to the current market price of $0.2581, the massive overhang from the warrants—potentially 9.7 million additional shares—creates extreme dilution risk. Net proceeds of approximately $3.59 million provide critical working capital for a company that has been burning cash and recently executed a 128-for-1 reverse split to maintain its Nasdaq listing. The offering follows a series of dilutive capital raises and shareholder approvals for astronomical authorized share increases, signaling ongoing financial distress. Trading near its 52-week low, the stock will face further pressure from this deal, necessary as it is for survival.